Xochelli Aliki, Oscier David, Stamatopoulos Kostas
Institute of Applied Biosciences, CERTH, Thessaloniki, Greece; Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Department of Haematology, Royal Bournemouth Hospital, Bournemouth, UK.
Best Pract Res Clin Haematol. 2017 Mar-Jun;30(1-2):77-83. doi: 10.1016/j.beha.2016.08.028. Epub 2016 Nov 4.
Monoclonal B cell Lymphocytosis (MBL) is the term used to characterize individuals presenting with lymphocytosis in the absence of lymphadenopathy, organomegaly or any other features suggestive of an active disease. Based on the immunophenotypic findings, MBL cases are sub-categorized into chronic lymphocytic leukemia (CLL)-like, atypical CLL and non-CLL MBL. The latter corresponds to cases with immunophenotypic features suggestive of post germinal center derivation and still represents a diagnostic conundrum. Recent studies are starting to shed light on the true biological nature and clinical significance of this entity and have led to the introduction of the novel term clonal B lymphocytosis of marginal-zone origin (CBL-MZ); as well as the acknowledgement of CBL-MZ in the latest (2016) update of the WHO classification for lymphoid malignancies. Here we provide an overview of relevant research concerning non-CLL MBL and discuss clinico-biological implications and considerations.
单克隆B淋巴细胞增多症(MBL)是用于描述那些淋巴细胞增多但无淋巴结病、器官肿大或任何其他提示活动性疾病特征的个体的术语。根据免疫表型结果,MBL病例可细分为慢性淋巴细胞白血病(CLL)样、非典型CLL和非CLL MBL。后者对应于具有提示生发中心后起源的免疫表型特征的病例,仍然是一个诊断难题。最近的研究开始揭示这一实体的真正生物学本质和临床意义,并导致引入了新术语边缘区起源的克隆性B淋巴细胞增多症(CBL-MZ);同时,在世界卫生组织淋巴系统恶性肿瘤分类的最新(2016年)更新中也认可了CBL-MZ。在此,我们概述了有关非CLL MBL的相关研究,并讨论临床生物学意义及注意事项。